摘要
多西环素(doxycycline)属于第二代四环素类药物,是土霉素的半合成衍生物。多西环素口服生物利用度较高、半衰期长、抗菌谱广,对革兰氏阳性菌、阴性菌所致的呼吸道疾病和细菌感染以及斑疹伤寒、疟疾、支原体肺炎等都具有较好的疗效,在儿童人群中主要用于耐大环内酯类的支原体肺炎和落基山斑疹热的治疗。由于四环素类药物说明书中只推荐≥8岁儿童使用,对于超说明书用药儿童人群的安全性,医疗卫生人员也给予极大的关注。因此,该文通过查阅文献总结多西环素在儿童人群(尤其是<8岁儿童)临床治疗中的安全性,以期为临床更好指导多西环素在儿童中的安全用药提供参考。
Doxycycline is a semisynthetic derivative of oxytetracycline that belongs to the second generation of tetracycline drugs.With high oral bioavailability,long half-life and wide antibacterial spectrum,doxycycline has a good effect on respiratory diseases and bacterial infections caused by Gram positive and negative bacteria,as well as typhus,malaria and mycoplasma pneumonia,etc.It is mainly used to treat macrolide resistant mycoplasma pneumonia and Rocky Mountain spotted fever in children.Instructions for tetracycline drugs only recommend the use in children at 8 years of age and older.Its safety in the application to younger children has been well concerned.Therefore,this article summarized the safety of doxycycline in the clinical treatment of children through literature review,especially those under 8 years old,thus providing references for a better clinical guidance on the safe use of doxycycline in children.
作者
高一波
王静林
郑锋
王广飞
袁道祎
吴丹
李智平
GAO Yibo;WANG Jinglin;ZHENG Feng;WANG Guangfei;YUAN Daoyi;WU Dan;LI Zhiping(Department of Clinical Pharmacy,Children's Hospital of Fudan University,National Children's Medical Center,Shanghai 201102,China;Department of Pharmacy,Union Hospital,Tongji Medical College of Huazhong University of Science and Technology,Hubei Wuhan 430022,China)
出处
《中国医院药学杂志》
北大核心
2025年第2期220-224,共5页
Chinese Journal of Hospital Pharmacy
基金
上海市医药卫生发展基金会(儿童抗感染药物精准用药)项目(编号:20221128)
2022年东方英才计划(原上海领军人才)项目(编号:EK00000861)。
关键词
多西环素
儿童
安全性研究
不良反应
doxycycline
children
safety research
adverse reaction
作者简介
高一波,男,硕士,药师,研究方向:儿科临床药学;通信作者:李智平,女,博士,主任药师,博士生导师,研究方向:儿科临床药理学。
